Home Amines 223472-31-9
223472-31-9,MFCD09971106
Catalog No.:AA00C4FH

223472-31-9 | N-[(1S,3S)-1-[(ETHOXYMETHOXY)METHYL]-4-(HYDROXYAMINO)-3-METHYL-4-OXOBUTYL]-4-PHENOXYBENZAMIDE

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
≥98%
in stock  
$152.00   $106.00
- +
5mg
≥98%
in stock  
$668.00   $467.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA00C4FH
Chemical Name:
N-[(1S,3S)-1-[(ETHOXYMETHOXY)METHYL]-4-(HYDROXYAMINO)-3-METHYL-4-OXOBUTYL]-4-PHENOXYBENZAMIDE
CAS Number:
223472-31-9
Molecular Formula:
C22H28N2O6
Molecular Weight:
416.4675
MDL Number:
MFCD09971106
SMILES:
CCOCOCC(NC(=O)c1ccc(cc1)Oc1ccccc1)CC(C(=O)NO)C
Properties
Computed Properties
 
Complexity:
504  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
2  
Heavy Atom Count:
30  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
12  
XLogP3:
2.6  

Literature

Title: Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity.

Journal: Biochemical and biophysical research communications 20120622

Title: Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats.

Journal: Arteriosclerosis, thrombosis, and vascular biology 20120301

Title: Mechanisms and interventions in peritoneal fibrosis.

Journal: Clinical and experimental nephrology 20120201

Title: Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury.

Journal: Circulation 20101116

Title: Significance of chymase-dependent matrix metalloproteinase-9 activation on indomethacin-induced small intestinal damages in rats.

Journal: The Journal of pharmacology and experimental therapeutics 20100201

Title: Significance of matrix metalloproteinase-9 in cardiac dysfunction during the very acute phase after myocardial infarction in hamsters.

Journal: European journal of pharmacology 20071015

Title: Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071001

Title: A matrix metalloproteinase inhibitor, ONO-4817, suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit.

Journal: International heart journal 20070501

Title: Hepatic ischemia/reperfusion injury is prevented by a novel matrix metalloproteinase inhibitor, ONO-4817.

Journal: Surgery 20060501

Title: Matrix metalloproteinase inhibitor (ONO-4817) attenuates ischemia-reperfusion injury in rat lung.

Journal: Medical science monitor : international medical journal of experimental and clinical research 20060201

Title: ONO-4817, a novel matrix metalloproteinase inhibitor, attenuates allograft vasculopathy in a rat cardiac transplant.

Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20041001

Title: An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20040901

Title: Effect of a synthetic matrix metalloproteinase inhibitor (ONO-4817) on neointima formation in hypercholesterolemic hamsters.

Journal: Journal of cardiovascular pharmacology 20040701

Title: Analgesic effect of intrathecally administered matrix metalloproteinase 2 (MMP-2) in the rat formalin test.

Journal: Neuroscience letters 20030821

Title: Effect of hydroxamic acid-based matrix metalloproteinase inhibitors on human gingival cells and Porphyromonas gingivalis.

Journal: Journal of periodontology 20030801

Title: Increased surgical stress promotes tumor metastasis.

Journal: Surgery 20030501

Title: A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice.

Journal: International journal of cancer 20030301

Title: The inhibitory effect of matrix metalloproteinase inhibitor ONO-4817 on lymph node metastasis in tongue carcinoma.

Journal: Anticancer research 20030101

Title: Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines.

Journal: Cancer research 20021015

Title: Therapeutic and analysis model of intrahepatic metastasis reflects clinical behavior of hepatocellular carcinoma.

Journal: Japanese journal of cancer research : Gann 20020201

Title: A matrix metalloproteinase inhibitor, ONO-4817, retards the development of mammary tumor and the progression of uterine adenomyosis in mice.

Journal: Anticancer research 20020101

Title: Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice.

Journal: Experimental biology and medicine (Maywood, N.J.) 20010501

Title: Effect of a matrix metalloproteinase inhibitor (ONO-4817) on lung metastasis of murine renal cell carcinoma.

Journal: Anticancer research 20010101

Title: ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20000401

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 223472-31-9
Tags:223472-31-9 Molecular Formula|223472-31-9 MDL|223472-31-9 SMILES|223472-31-9 N-[(1S,3S)-1-[(ETHOXYMETHOXY)METHYL]-4-(HYDROXYAMINO)-3-METHYL-4-OXOBUTYL]-4-PHENOXYBENZAMIDE